Clinical trials: Cardiac Ischemia
Hypercholesterolemia, Atherosclerotic Disease
Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)
A 6-week treatment study to compare the reduction in cholesterol of two drugs MK0653A+Simvastatin for high cholesterol, in patients with hypercholesterolemia and atherosclerotic or coronary vascular disease.
- Conditions
- Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease
- Trial name
- NCT00090168
- Testing
- MK0653A , ezetimibe (+) simvastatin, Comparator: atorvastatin, Duration of Treatment: 6 weeks
- Volunteers
- 435 people
- Sponsor
- Organon and Co
Acute Coronary Syndrome
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome
The study will compare the safety and efficacy of prasugrel, administered at different doses with clopidogrel in the treatment of Asian participants with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
- Trial name
- NCT00830960
- Testing
- Prasugrel, Clopidogrel
- Where
- 19 sites in China, South Korea and 2 more
- Volunteers
- 720 people
- Sponsor
- Eli Lilly and Company
Coronary Heart Disease
Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)
To evaluate the safety and efficacy of MiStent drug (sirolimus)-eluting stent system in the treatment of coronary heart disease (CHD) in patients with primary in situ CHD (de novo); To evaluate operating performance of the…
- Trial name
- DESSOLVE-C (NCT02448524)
- Testing
- MiStent, TIVOLI
- Where
- 16 sites in China
- Volunteers
- 428 people
- Sponsor
- Micell Technologies
Atrial Fibrillation
Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)
This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater.
- Trial name
- EVOLVE (NCT01196897)
- Testing
- WATCHMAN LAA Closure Technology (Gen 4.0)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 69 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Angina Pectoris
Understanding the Effect of Metformin on Corus CAD (or ASGES)
The study goal was to understand the effect of Metformin on Age/Sex/Gene Expression Score (ASGES) or Corus CAD (henceforth "Corus") in pre-diabetic patients who are medication naive.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- MET (NCT02440893)
- Testing
- Corus CAD (ASGES)
- Volunteers
- 37 people
- Sponsor
- CardioDx
Coronary Artery Disease, Myocardial Ischemia
The eSVS® Mesh Randomized Post-Market Study
The purpose of this study is to evaluate patency rates of the external Saphenous Vein Support (eSVS) Mesh Saphenous Vein Grafts (SVG) and Control SVG at 3-6 months and 24 months.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases
- Trial name
- NCT01462721
- Testing
- eSVS® Mesh
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Kips Bay Medical, Inc.
Coronary Artery Disease, Myocardial Ischemia
Bare Metal Bifurcation Stent Clinical Trial in Humans
To assess the feasibility and safety of the Medtronic Bifurcation Stent System for the treatment of single de novo bifurcation lesions in native coronary arteries with reference vessel diameters (RVD) for the proximal main vessel…
- Trial name
- BRANCH (NCT00607321)
- Testing
- Medtronic Bifurcation Stent System
- Where
- New Zealand
- Volunteers
- 60 people
- Sponsor
- Medtronic Vascular
Stents, Coronary Artery Disease
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V®…
- Conditions
- Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis
- Trial name
- NCT00180479
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries
To investigate the safety and efficacy of the Cinatra™ Corolimus Drug Eluting Stent for the treatment of de novo lesions in native coronary arteries.
- Trial name
- VANTAGE-1 (NCT01025869)
- Testing
- Cinatra™ Corolimus Eluting Coronary Stent System
- Where
- 4 sites in New Zealand
- Volunteers
- 31 people
- Sponsor
- Atrium Medical Corporation
Coronary Artery Disease
Multicentre Registry of CCTA, IVUS and OCT
The Invictus Registry will compare the diagnostic performance of coronary computed tomography angiography (CCTA) versus intravascular imaging by intravenous ultrasound (IVUS) or optical coherence tomography (OCT) for the…
- Trial name
- NCT04066062
- Where
- 9 sites in Japan
- Volunteers
- 1,700 people
- Sponsor
- Cleerly, Inc.
Coronary Artery Disease
Registry for CARDIAC PERFUSION CT
This protocol describes a study whose goal is to collect de-identified Cardiac CT Perfusion (CTP) acquisition parameters and clinical findings from approximately 20 qualified medical facilities.
- Trial name
- RECRUIT (NCT01346605)
- Where
- United States
- Sponsor
- MDDX LLC
Myocardial Ischemia, Coronary Artery Disease
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
This is a multi-centre, open-label, single-dose safety, tolerability and PK-pharmacodynamics (PD) study of the vasodilator regadenoson in 3 paediatric age groups for whom a pharmacologic stress perfusion CMR test is clinically…
- Trial name
- Rapiscan PIP (NCT04604782)
- Testing
- Regadenoson
- Where
- 5 sites in France, Greece and 2 more
- Volunteers
- 54 people
- Sponsor
- GE Healthcare
Stable Angina Pectoris
Extended-Release RANCAD in the Patients With Stable Angina Pectoris
A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.
- Trial name
- NCT02294942
- Testing
- RANCAD
- Where
- 6 sites in Taiwan
- Volunteers
- 75 people
- Sponsor
- TSH Biopharm Corporation Limited
Atherosclerotic Coronary Vascular Disease
Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease
The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).
- Trial name
- NCT01562041
- Testing
- Ranolazine 500 mg
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care
The objective of the HeartFlow ADVANCE Registry is to evaluate utility, clinical outcomes and resource utilization of FFRCT-guided evaluation in clinically stable, symptomatic patients with coronary artery disease (CAD) in order…
- Trial name
- ADVANCE (NCT02499679)
- Volunteers
- 4,737 people
- Sponsor
- HeartFlow, Inc.
Acute Coronary Syndrome
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.
- Trial name
- NCT00552188
- Testing
- VIA-2291
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Coronary Artery Disease
Vis-Rx Post-Market Evaluation
Post-market clinical evaluation of the Gentuity High-Frequency Optical Coherence Tomography (HF-OCT) System and the Vis-Rx Micro-Imaging Catheter for use in Percutaneous Coronary Intervention (PCI) procedures.
- Trial name
- Vis-Rx PME (NCT04533503)
- Testing
- HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter
- Where
- 3 sites in United States
- Volunteers
- 257 people
- Sponsor
- Gentuity, LLC
Angina
Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in approximately 500 patients with chronic angina who remain…
- Trial name
- NCT00091429
- Testing
- Ranolazine
- Volunteers
- 500 people
- Sponsor
- Gilead Sciences
Heart Failure
Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
Evaluation the safety and efficacy of C3BS-CQR-1 by comparing the overall response to standard of care and C3BS-CQR-1 relative to standard of care and a sham procedure.
- Trial name
- CHART-1 (NCT01768702)
- Testing
- Injection of C3BS-CQR-1
- Where
- 35 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 315 people
- Sponsor
- Celyad Oncology SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.